Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer

Breast Cancer: Basic and Clinical Research

Review

Ronald Blasberg¹  Ivan J Cohen² 

[1] Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA;Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA;Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA;Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY USA;

关键词: Breast cancer;    immunotherapy;    immune evasion;    tumor metabolism;    tumor infiltrating lymphocytes;   

DOI  :  10.1177/1178223417731565

 received in 2017-05-24, accepted in 2017-08-14,  发布年份 2017

来源: Sage Journals

【 摘 要 】

Immunotherapy is revolutionizing cancer care across disciplines. The original success of immune checkpoint blockade in melanoma has already been translated to Food and Drug Administration–approved therapies in a number of other cancers, and a large number of clinical trials are underway in many other disease types, including breast cancer. Here, we review the basic requirements for a successful antitumor immune response, with a focus on the metabolic and physical barriers encountered by lymphocytes entering breast tumors. We also review recent clinical trials of immunotherapy in breast cancer and provide a number of interesting questions that will need to be answered for successful breast cancer immunotherapy.

【 授权许可】

CC BY-NC   
© The Author(s) 2017

【 图 表 】

Figure 3